Revelation Biosciences Inc. (NASDAQ: REVB)
$1.86
-0.0100 ( -0.54% ) 363.8K
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
Market Data
Open
$1.86
Previous close
$1.87
Volume
363.8K
Market cap
$3.04M
Day range
$1.79 - $2.02
52 week range
$1.61 - $28.20
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 46 | Oct 12, 2023 |
8-k | 8K-related | 15 | Oct 02, 2023 |
3 | Insider transactions | 2 | Oct 02, 2023 |
4 | Insider transactions | 1 | Oct 02, 2023 |
4 | Insider transactions | 1 | Sep 18, 2023 |
8-k | 8K-related | 13 | Aug 11, 2023 |
10-q | Quarterly Reports | 66 | Aug 11, 2023 |
8-k | 8K-related | 15 | Aug 11, 2023 |
8-k | 8K-related | 13 | Jul 14, 2023 |
8-k | 8K-related | 14 | Jul 07, 2023 |